Abstract
The CXC chemokines are an unique family of cytokines known for their ability to behave in a disparate manner in the regulation of angiogenesis. The mechanisms for the different activity in regulating angiogenesis by members of this chemokine family is related to the following: 1) the presence or absence of the structural / functional motif (Glutamic acid-Leucine-Arginine; ‘ELR’ motif) that immediately precedes the first cysteine amino acid residue in the primary structure of these cytokines; 2) interferon-inducible gene expression; and 3) receptors that these chemokines use to mediate their biological activity. Members that contain the ‘ELR’ motif (ELR+) are potent promoters of angiogenesis, and mediate their angiogenic activity via binding and activating CXCR2 on endothelium. In contrast, members that are inducible by interferons and lack the ELR motif (ELR-) are potent inhibitors of angiogenesis, and bind to the alternatively splice variant of CXCR3, CXCR3B on endothelium. This review will discuss the biology of these angiogenic and angiostatic CXC chemokines, and discuss their disparate angiogenic activity in the context of a variety of chronic fibroproliferative disorders.
Keywords: cytokines, angiogenesis, neovascularization, chronic fibroproliferative disorders
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Recent Advances in Anti-Infective Drug Discovery
Related Books
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
Anti-Obesity Drug Discovery and Development
17